Dr. JEANNE completed his PhD in biochemistry and cell biology within CNRS 7369 MEDyC research unit. He has authored 15 peer-reviewed scientific publications on TSP-1 pathobiology and won numerous international awards. During past professional experience as a project manager, he developed his expertise in translational drug development while building capacity to manage research programs, partnerships, and reach deliverables. As a co-inventor of TAX2 patents, he engineered the first ever antagonists being selective for TSP- 1/CD47 interaction. Beyond scientific background, Albin JEANNE acquired strong management skills and strategic insights as he completed the Challenge+ program at HEC international business school. He co-founded Apmonia Therapeutics early 2019 and serves as President and CSO.